StreetAlpha.app
Home › Stocks › ACXP

Acurx Pharmaceuticals, Inc. (ACXP)

$0.99
▲ +5.88%
LAST CLOSE · NOV 17

Acurx Pharmaceuticals develops new antibiotics for hard to treat bacterial infections, based in Staten Island, New York. It last closed at $0.99 on Nov 17, up 5.88% on the day.

AI Auto Pilots
Is ACXP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$8.1M
EPS (diluted)
−$1.90
Valuation
Market cap
$6.0M
6.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.7M
At Sep 30
Shareholder equity
$7.3M
Shares outstanding
6.1M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$12.7M−$12.7MFY2021FY2022: −$12.1M−$12.1MFY2022FY2023: −$14.6M−$14.6MFY2023FY2024: −$14.1M−$14.1MFY2024FY2025: −$8.0M−$8.0MFY2025

From ACXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ACXP in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 1011.1% upside

Based on 1 analyst who set a price target on ACXP in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $0.99.

Low $11.00Avg $11.00High $11.00
Blue marker: last close $0.99
Highest target$11.00
Average target$11.00
Lowest target$11.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 12Buy$31 → $11
HC Wainwright & Co.Reiterated
Sep 29Buy$31
DateFirmActionRatingPrice target
Nov 12HC Wainwright & Co.Target loweredBuy$31 → $11
Sep 29HC Wainwright & Co.ReiteratedBuy$31
Loading…

Technical Analysis

ACXP · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 21% below its 50 day average. It is 90% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $0.95, and the nearest resistance the Pivot R1 at $1.03.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 7.7%/day
Key levels
$7.5452 week high+661.6%
$1.88200 day average+89.9%
$1.34100 day average+35.4%
$1.2050 day average+21.2%
$1.11Swing high (Nov 3)+12.1%
$1.0420 day average+5.1%
$1.03Pivot R1+4.0%
$0.99Pivot+0.0%
$0.99Last close
$0.95Pivot S1−4.0%
$0.95Swing low (Nov 5)−4.0%
$0.9252 week low−7.1%
Indicators
RSI (14)39.34Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic21.3Middle of its rangeNeutral
ADX (14)39.8Trending down
Williams %R-64.6Oversold below −80, overbought above −20Neutral
CCI (20)-107.0Oversold below −100, overbought above 100Oversold
Rate of change−2.9%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACXP

What happened before

See how ACXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACXP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACXP in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 8 selling
  • ▲Held by funds +0.9 pts
  • ●Funds holding +0
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding19190.0%
In funds' top 1000–
Held by funds3.0%2.0%+0.9 pts
New / increased3 / 32 / 3+20.0%
Reduced / sold out5 / 34 / 40.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACXP is in one of them and how their past ACXP trades turned out.

ACXP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACXP in an article yet. Here's the latest on the wider market.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals is a biopharmaceutical company based in Staten Island, New York. It is developing a new class of small molecule antibiotics for bacterial infections that are hard to treat, including Clostridioides difficile infections, MRSA, and vancomycin resistant Enterococcus. Its lead candidate, ibezapolstat, works by blocking a bacterial enzyme called DNA pol IIIC and is in clinical trials. The company expects to partner with a larger drugmaker for later stage trials and commercialization, and its intended users are patients with these infections and the healthcare providers who treat them.

Headquarters
Staten Island, NY